Maze Therapeutics (MAZE) Liabilities and Shareholders Equity (2024 - 2026)

Maze Therapeutics' Liabilities and Shareholders Equity history runs 3 years deep, the most recent figure standing at $419.7 million for Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity rose 26.1% year-over-year to $419.7 million; the TTM figure through Mar 2026 stood at $1.5 billion (up 169.0% YoY), while the FY2025 annual figure was $397.1 million, up 65.1% from the prior year.
• Liabilities and Shareholders Equity came in at $419.7 million for Q1 2026 at Maze Therapeutics, up from $397.1 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $422.1 million in Q3 2025 to a low of $240.5 million in Q4 2024.
• A 3-year average of $352.6 million and a median of $365.0 million in 2025 frame the typical range for Liabilities and Shareholders Equity.
• Across the five-year window, Liabilities and Shareholders Equity soared 65.1% in 2025 and climbed 26.1% in 2026, its largest moves.
• Maze Therapeutics' Liabilities and Shareholders Equity stood at $240.5 million in 2024, then jumped by 65.1% to $397.1 million in 2025, then gained by 5.69% to $419.7 million in 2026.
• According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $419.7 million, $397.1 million, and $422.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison